Nimbus Therapeutics has closed a $210m fundraising round involving existing and new investors, notably GV or Google Ventures. This comes more than six months since Nimbus closed a high-profile deal with Takeda Pharmaceuticals where the latter acquired a subsidiary in a deal that holds the potential to yield multi-billion dollar milestone-based payments.
Over the years, Nimbus has accrued an impressive list of private investors and venture capital. In a $125 million round announced in September 2022, Bain Capital and SV Health investors joined existing investors, which include Atlas Venture, Bill Gates, Pfizer Ventures, RA Capital Management, amongst others, as per GlobalData’s Deals database.
GlobalData is the parent company of Pharmaceutical Technology.
GV featured as a new investor in the latest round. Dr. Krishna Yeshwant, general partner at GV, highlighted the company’s expertise in “integrating cutting-edge computational chemistry, high-tech structural biology tools and other industry-shaping technologies and approaches” in the announcement accompanying the fundraise.
Nimbus relies on a computational chemistry-led platform to exploit protein structure data and identify potential drug targets. As per the company, the differentiating factor here is its interdisciplinary work across biophysics, protein discover, enzymology and screening. The latest financing is supposed to aid the development of other programs that target enzyme and autoimmune disorders in preclinical and clinical stages.
As part of the deal that closed in February, Takeda acquired NDI-034858 a tyrosine kinase 2 (TYK2) inhibitor being developed for several autoimmune diseases. As per GlobalData, the acquisition aligned well with Takeda’s expertise in immune-mediated diseases, and added to its late-stage pipeline. NDI-034858 is currently in Phase II clinical trials.
Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.
Source link
#Signal #Nimbus #raises #210m #foster #drug #discovery #plans
